代谢综合征、失眠和褪黑激素

V.A. Serhiyenko, V. B. Sehin, M. Hotsko, L. Serhiyenko, О.О. Serhiyenko
{"title":"代谢综合征、失眠和褪黑激素","authors":"V.A. Serhiyenko, V. B. Sehin, M. Hotsko, L. Serhiyenko, О.О. Serhiyenko","doi":"10.22141/2224-0721.20.2.2024.1375","DOIUrl":null,"url":null,"abstract":"In recent years, there has been an interest in studying the specifics of the relationships between metabolic syndrome (MetS), sleep disorders and melatonin (MEL). Dyssomnia and insomnia are important risk factors for insulin resistance, obesity, MetS, and type 2 diabetes mellitus with a degree of influence similar to traditional factors. Thus, the treatment of dyssomnia is one of the key tasks in the prevention and treatment of MetS. The regulation of sleep and circadian rhythms by exogenous intervention (in particular, the use of melatonergic drugs) is likely to play a central role in the prevention and treatment of dyssomnia in MetS. MEL acts as a powerful antioxidant that can cross the blood-brain barrier, suppress oxidative stress, chronic inflammation, and interact with the gut microbiome. From a clinical point of view, an imbalance of MEL may indicate a “darkness deficit”. It has been proven that the neurohormone has systemic effects due to its mechanisms of action, the potential to influence the course of many chronic diseases. Currently, melatonergic drugs are approved exclusively for the treatment of insomnia, jetlag, and depression accompanied by sleep disorders. However, MEL potentially has therapeutic properties in the treatment of neurodegenerative diseases, post-traumatic stress disorder, neuropsychiatric disorders, dementia, autoimmune and allergic diseases. The increasing need for the use of MEL products has prompted the search for safe but environmentally friendly medicines. It is reported that phytomelatonin may have advantages related to improved bioavailability and efficacy. The purpose of this review is to analyze the specifics of the relationship between MetS, dyssomnia, and MEL. The search was conducted in Scopus, Science Direct (from Else­vier), and PubMed, including MEDLINE databases. The keywords used were “metabolic syndrome”, “dyssomnia”, “insomnia”, “obstructive sleep apnea”, and “melatonin”. We conducted a manual search of the bibliography of publications to identify research results that were eluded during the online search.","PeriodicalId":13962,"journal":{"name":"INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","volume":" 42","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metabolic syndrome, dyssomnia, and melatonin\",\"authors\":\"V.A. Serhiyenko, V. B. Sehin, M. Hotsko, L. Serhiyenko, О.О. Serhiyenko\",\"doi\":\"10.22141/2224-0721.20.2.2024.1375\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In recent years, there has been an interest in studying the specifics of the relationships between metabolic syndrome (MetS), sleep disorders and melatonin (MEL). Dyssomnia and insomnia are important risk factors for insulin resistance, obesity, MetS, and type 2 diabetes mellitus with a degree of influence similar to traditional factors. Thus, the treatment of dyssomnia is one of the key tasks in the prevention and treatment of MetS. The regulation of sleep and circadian rhythms by exogenous intervention (in particular, the use of melatonergic drugs) is likely to play a central role in the prevention and treatment of dyssomnia in MetS. MEL acts as a powerful antioxidant that can cross the blood-brain barrier, suppress oxidative stress, chronic inflammation, and interact with the gut microbiome. From a clinical point of view, an imbalance of MEL may indicate a “darkness deficit”. It has been proven that the neurohormone has systemic effects due to its mechanisms of action, the potential to influence the course of many chronic diseases. Currently, melatonergic drugs are approved exclusively for the treatment of insomnia, jetlag, and depression accompanied by sleep disorders. However, MEL potentially has therapeutic properties in the treatment of neurodegenerative diseases, post-traumatic stress disorder, neuropsychiatric disorders, dementia, autoimmune and allergic diseases. The increasing need for the use of MEL products has prompted the search for safe but environmentally friendly medicines. It is reported that phytomelatonin may have advantages related to improved bioavailability and efficacy. The purpose of this review is to analyze the specifics of the relationship between MetS, dyssomnia, and MEL. The search was conducted in Scopus, Science Direct (from Else­vier), and PubMed, including MEDLINE databases. The keywords used were “metabolic syndrome”, “dyssomnia”, “insomnia”, “obstructive sleep apnea”, and “melatonin”. We conducted a manual search of the bibliography of publications to identify research results that were eluded during the online search.\",\"PeriodicalId\":13962,\"journal\":{\"name\":\"INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)\",\"volume\":\" 42\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22141/2224-0721.20.2.2024.1375\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22141/2224-0721.20.2.2024.1375","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

近年来,人们开始关注研究代谢综合征(MetS)、睡眠障碍和褪黑激素(MEL)之间关系的具体细节。失眠是导致胰岛素抵抗、肥胖、代谢综合征和 2 型糖尿病的重要危险因素,其影响程度与传统因素类似。因此,治疗失眠是预防和治疗 MetS 的关键任务之一。通过外源性干预(特别是使用褪黑激素药物)来调节睡眠和昼夜节律,可能会在预防和治疗 MetS 失眠症中发挥核心作用。褪黑激素是一种强大的抗氧化剂,可以穿过血脑屏障,抑制氧化应激和慢性炎症,并与肠道微生物群相互作用。从临床角度来看,MEL 的失衡可能预示着 "黑暗缺失"。事实证明,这种神经激素的作用机制具有全身效应,有可能影响许多慢性疾病的病程。目前,褪黑激素类药物被批准专门用于治疗失眠、时差和伴有睡眠障碍的抑郁症。然而,褪黑激素在治疗神经退行性疾病、创伤后应激障碍、神经精神障碍、痴呆症、自身免疫性疾病和过敏性疾病方面具有潜在的治疗特性。对使用 MEL 产品的需求日益增加,促使人们寻找安全而又环保的药物。据报道,植物褪黑素可能具有提高生物利用度和疗效的优势。本综述旨在分析 MetS、失眠和 MEL 之间关系的具体细节。检索在 Scopus、Science Direct(来自 Elsevier)和 PubMed(包括 MEDLINE)数据库中进行。使用的关键词包括 "代谢综合征"、"失眠"、"失眠症"、"阻塞性睡眠呼吸暂停 "和 "褪黑激素"。我们对出版物的书目进行了人工搜索,以找出在线搜索中忽略的研究成果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Metabolic syndrome, dyssomnia, and melatonin
In recent years, there has been an interest in studying the specifics of the relationships between metabolic syndrome (MetS), sleep disorders and melatonin (MEL). Dyssomnia and insomnia are important risk factors for insulin resistance, obesity, MetS, and type 2 diabetes mellitus with a degree of influence similar to traditional factors. Thus, the treatment of dyssomnia is one of the key tasks in the prevention and treatment of MetS. The regulation of sleep and circadian rhythms by exogenous intervention (in particular, the use of melatonergic drugs) is likely to play a central role in the prevention and treatment of dyssomnia in MetS. MEL acts as a powerful antioxidant that can cross the blood-brain barrier, suppress oxidative stress, chronic inflammation, and interact with the gut microbiome. From a clinical point of view, an imbalance of MEL may indicate a “darkness deficit”. It has been proven that the neurohormone has systemic effects due to its mechanisms of action, the potential to influence the course of many chronic diseases. Currently, melatonergic drugs are approved exclusively for the treatment of insomnia, jetlag, and depression accompanied by sleep disorders. However, MEL potentially has therapeutic properties in the treatment of neurodegenerative diseases, post-traumatic stress disorder, neuropsychiatric disorders, dementia, autoimmune and allergic diseases. The increasing need for the use of MEL products has prompted the search for safe but environmentally friendly medicines. It is reported that phytomelatonin may have advantages related to improved bioavailability and efficacy. The purpose of this review is to analyze the specifics of the relationship between MetS, dyssomnia, and MEL. The search was conducted in Scopus, Science Direct (from Else­vier), and PubMed, including MEDLINE databases. The keywords used were “metabolic syndrome”, “dyssomnia”, “insomnia”, “obstructive sleep apnea”, and “melatonin”. We conducted a manual search of the bibliography of publications to identify research results that were eluded during the online search.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信